Clinical Proteomics

CellCarta’s clinical proteomics capabilities include our ability to develop and validate assays for use in clinical trials as part of a comprehensive biomarker program. We offer both custom and off-the-shelf assays to facilitate rapid screening and verification of large numbers of candidate protein biomarkers. Our rigorous assay development approach follows CPTAC guidelines, covering all important assay characteristics (sensitivity, specificity, reproducibility, stability, recovery, matrix effects, etc.), as needed.

Mass spectrometry is a highly quantitative technique that is increasingly being used for the measurement of protein biomarkers in a clinical setting. Where other techniques fall short, mass spectrometry may offer an ideal solution to quantify biomarkers.

Find out more about our Mass Spectrometry platform.

Monitoring biomarkers of interest is achieved using multiple reaction monitoring (MRM), a multiplexed quantitative mass spectrometry approach with several advantages:

• Antibody-free approach
• Multiplex assays easily expandable to incorporate new target proteins
• Use of stable isotope-labeled peptide standards facilitating precise and accurate quantitation
• High sensitivity and specificity through targeted MRM using GCLP-compliant instruments
• Possibility to further increase sensitivity through enrichment of low abundance proteins using antibodies or chromatography
• Post-translational modifications (PTMs) detection

Monitor the expression of soluble B-cell maturation antigen (BCMA) in your clinical plasma samples using our MRM platform.

Using a targeted and quantitative approach, harness the potential of readily available and stable formalin-fixed paraffin embedded (FFPE) samples to measure clinically relevant biomarkers.

In addition of our expertise in multiplex MRM assays, CellCarta offers high-quality unbiased liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) services to help you discover new biomarkers.